by Maria Zannes | Jul 24, 2018 | News
JULY 19, 2018 As published in the San Antonio Business Journal By W. Scott Bailey Roughly four years after its San Antonio launch, cancer diagnostics company bioAffinity Technologies is only months away from taking its initial product — CyPath Lung — to market. The...
by Maria Zannes | Jul 23, 2018 | Press Releases
JULY 17, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has commenced its test validation trial for CyPath® Lung, an advanced flow cytometry test for the early detection of lung cancer. Recruitment is...
by Maria Zannes | May 18, 2018 | News
MAY 15, 2018 As published in Xconomy Texas By David Holley (SAN ANTONIO, TX) bioAffinity, the maker of a cancer diagnostic test, has added Peter Knight, who was the chief of staff for Al Gore when he was in Congress, to its board of directors and is in the process of...
by Maria Zannes | May 18, 2018 | Press Releases
MAY 14, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Peter S. Knight, founding partner of Generation Investment Management, to its Board of...
by Maria Zannes | Mar 15, 2018 | News
MARCH 1, 2018 As published in the San Antonio Business Journal By W. Scott Bailey San Antonio-based bioAffinity Technologies has been approved for membership in the Early Detection Research Network, an initiative of the National Cancer Institute. The approval gives...
